Literature DB >> 16357170

Hypoxia-induced down-regulation of BRCA1 expression by E2Fs.

Ranjit S Bindra1, Shannon L Gibson, Alice Meng, Ulrica Westermark, Maria Jasin, Andrew J Pierce, Robert G Bristow, Marie K Classon, Peter M Glazer.   

Abstract

Decreased BRCA1 expression in the absence of genetic mutation is observed frequently in sporadic cancers of the breast and other sites, although little is known regarding the mechanisms by which the expression of this gene can be repressed. Here, we show that activating and repressive E2Fs simultaneously bind the BRCA1 promoter at two adjacent E2F sites in vivo, and that hypoxia induces a dynamic redistribution of promoter occupancy by these factors resulting in the transcriptional repression of BRCA1 expression. Functionally, we show that hypoxia is associated with impaired homologous recombination, whereas the nonhomologous end-joining (NHEJ) repair pathway is unaffected under these conditions. Repression of BRCA1 expression by hypoxia represents an intriguing mechanism of functional BRCA1 inactivation in the absence of genetic mutation. We propose that hypoxia-induced decreases in BRCA1 expression and consequent suppression of homologous recombination may lead to genetic instability by shifting the balance between the high-fidelity homologous recombination pathway and the error-prone NHEJ pathway of DNA repair. Furthermore, these findings provide a novel link between E2Fs and the transcriptional response to hypoxia and provide insight into the mechanisms by which the tumor microenvironment can contribute to genetic instability in cancer.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16357170     DOI: 10.1158/0008-5472.CAN-05-2119

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  142 in total

Review 1.  Tumor hypoxia and genetic alterations in sporadic cancers.

Authors:  Minoru Koi; Clement R Boland
Journal:  J Obstet Gynaecol Res       Date:  2011-01-27       Impact factor: 1.730

2.  Exposure to acute hypoxia induces a transient DNA damage response which includes Chk1 and TLK1.

Authors:  Isabel M Pires; Zuzana Bencokova; Chris McGurk; Ester M Hammond
Journal:  Cell Cycle       Date:  2010-07-01       Impact factor: 4.534

3.  Hypoxic stress facilitates acute activation and chronic downregulation of fanconi anemia proteins.

Authors:  Susan E Scanlon; Peter M Glazer
Journal:  Mol Cancer Res       Date:  2014-03-31       Impact factor: 5.852

4.  E2F4 regulates a stable G2 arrest response to genotoxic stress in prostate carcinoma.

Authors:  M E Crosby; J Jacobberger; D Gupta; R M Macklis; A Almasan
Journal:  Oncogene       Date:  2006-10-09       Impact factor: 9.867

Review 5.  DNA repair and personalized breast cancer therapy.

Authors:  Shu-Xia Li; Ashley Sjolund; Lyndsay Harris; Joann B Sweasy
Journal:  Environ Mol Mutagen       Date:  2010 Oct-Dec       Impact factor: 3.216

Review 6.  E2F4 function in G2: maintaining G2-arrest to prevent mitotic entry with damaged DNA.

Authors:  Dragos Plesca; Meredith E Crosby; Damodar Gupta; Alexandru Almasan
Journal:  Cell Cycle       Date:  2007-05-11       Impact factor: 4.534

7.  Stress-Induced Mutagenesis: Implications in Cancer and Drug Resistance.

Authors:  Devon M Fitzgerald; P J Hastings; Susan M Rosenberg
Journal:  Annu Rev Cancer Biol       Date:  2017-03

8.  BNIP3 is an RB/E2F target gene required for hypoxia-induced autophagy.

Authors:  Kristin Tracy; Benjamin C Dibling; Benjamin T Spike; James R Knabb; Paul Schumacker; Kay F Macleod
Journal:  Mol Cell Biol       Date:  2007-06-18       Impact factor: 4.272

9.  MicroRNA regulation of DNA repair gene expression in hypoxic stress.

Authors:  Meredith E Crosby; Ritu Kulshreshtha; Mircea Ivan; Peter M Glazer
Journal:  Cancer Res       Date:  2009-01-13       Impact factor: 12.701

Review 10.  Hypoxic tumor microenvironment and cancer cell differentiation.

Authors:  Yuri Kim; Qun Lin; Peter M Glazer; Zhong Yun
Journal:  Curr Mol Med       Date:  2009-05       Impact factor: 2.222

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.